An updated BMS consensus statement is now available on the BMS website on the topic of Genitourinary Syndrome of Menopause (GSM).
Genitourinary Syndrome of Menopause (GSM) is a chronic and progressive condition due to estrogen deficiency, most commonly associated with the menopause. There is a potential negative impact on all urogenital tissue quality including the vulva, vagina, bladder and urethra.
Previously referred to as urogenital atrophy or vulvovaginal atrophy, the updated NICE menopause guideline 2024 refers to this combination of atrophic changes and symptoms as ‘genitourinary symptoms of the menopause’. Genitourinary Syndrome of Menopause (GSM) is now the internationally accepted term however, reflecting the impact of fluctuating or low levels of estrogen on urogenital tissue quality.
This resource replaces the BMS consensus statement on urogenital atrophy, last updated in March 2024.